Hope Biosciences Earns FDA RMAT for MS Stem Cell Therapy
Hope Biosciences Receives FDA RMAT Designation for Stem Cell Therapy in Relapsing-Remitting Multiple Sclerosis Hope Biosciences, a leading U.S.-based stem cell banking and cellular therapeutics manufacturer, has announced a major…
DNAnexus Strengthens Leadership Team to Drive AI Advances and Biopharma Growth
DNAnexus Expands Leadership to Drive AI Innovation and Biopharma Growth DNAnexus, Inc., a leader in enterprise solutions for precision health data, has unveiled a series of strategic leadership appointments that…
Tasso and SheMed Launch At-Home Blood Testing for UK Women
Tasso and SheMed Partner to Deliver At-Home Blood Testing for Safer, Personalized GLP-1 Treatments in the UK In a move that could transform how women access and experience weight loss…
Fresenius Launches EASYGEN to Decentralize CAR-T Therapy
Fresenius Leads EASYGEN Consortium to Decentralize CAR-T Cell Therapy and Improve Patient Access Across Europe The global healthcare company Fresenius has announced the launch of a major new initiative aimed…
Insulet Names Eric Benjamin as New Chief Operating Officer
Insulet Elevates Eric Benjamin to Chief Operating Officer and Appoints Manoj Raghunandanan as Chief Growth Officer, Strengthening Leadership to Drive Next Phase of Global Expansion Insulet Corporation (NASDAQ: PODD), the…
Varian Wraps Up Enrollment in FAST-02 Flash Therapy Trial
Varian Completes Enrollment and Treatment in FAST-02 Clinical Trial, Marking Major Milestone for Flash Radiotherapy in Thoracic Bone Metastases Varian, a Siemens Healthineers company and a global leader in radiation…
Evolus Reports Positive Pivotal Trial Results for Evolysse™ Sculpt at 2025 Cosmetic Bootcamp
Evolus Reports Positive Pivotal Trial Data for Evolysse™ Sculpt Hyaluronic Acid Gel at 2025 Cosmetic Bootcamp, Marking a Major Milestone in Aesthetic Innovation Evolus, Inc. (NASDAQ: EOLS), a fast-growing performance…
Merz Therapeutics Enrolls First Patients in Phase III Trials of XEOMIN® for Migraine Prevention
Merz Therapeutics Advances Migraine Research With Enrollment of First Patients in Two Global Phase III Clinical Trials for XEOMIN® (incobotulinumtoxinA) Merz Therapeutics GmbH, a neurology-focused specialty pharmaceutical company, announced a…
Xeris Secures Orange Book Listing for U.S. Patent on Recorlev®XerisXeris Secures Orange Book Listing for U.S. Patent on Recorlev®
Xeris Biopharma Strengthens Long-Term Market Position with Orange Book Listing of New U.S. Patent for Recorlev® Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly expanding biopharmaceutical company focused on developing…
Merck Showcases New Cardiovascular Data at ESC 2025
Merck Reinforces Global Commitment to Cardiovascular Research with New Data Presentations at ESC Congress 2025 in Madrid Merck (NYSE: MRK), known as MSD outside the United States and Canada, has…
BeOne Medicines Secures Up to $950 Million Through IMDELLTRA Royalty Deal
BeOne Medicines Strikes $950 Million Royalty Deal with Royalty Pharma for IMDELLTRA, Strengthening Oncology Strategy and Financial Flexibility BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused…
Devonian Issues Corporate Update and Details on Ongoing Private Placement
Devonian Health Group Provides Strategic Corporate Update and Clarifies Details of Private Placement Financing Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company…